PCSA
Price:
$1.15
Market Cap:
$3.75M
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, wh...[Read more]
Industry
Biotechnology
IPO Date
2014-03-07
Stock Exchange
NASDAQ
Ticker
PCSA
According to Processa Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 950.86K. This represents a change of -49.79% compared to the average of 1.89M of the last 4 quarters.
The mean historical Enterprise Value of Processa Pharmaceuticals, Inc. over the last ten years is 51.48M. The current 950.86K Enterprise Value has changed 84.71% with respect to the historical average. Over the past ten years (40 quarters), PCSA's Enterprise Value was at its highest in in the June 2018 quarter at 169.50M. The Enterprise Value was at its lowest in in the March 2024 quarter at -2983653.95.
Average
51.48M
Median
27.40M
Minimum
4.22M
Maximum
143.02M
Discovering the peaks and valleys of Processa Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 3.18%
Maximum Annual Enterprise Value = 143.02M
Minimum Annual Increase = -80.48%
Minimum Annual Enterprise Value = 4.22M
Year | Enterprise Value | Change |
---|---|---|
2023 | 4.22M | -63.14% |
2022 | 11.45M | -80.48% |
2021 | 58.65M | 70.62% |
2020 | 34.37M | -65.51% |
2019 | 99.65M | -25.00% |
2018 | 132.86M | -7.11% |
2017 | 143.02M | 3.18% |
2016 | 4.36M | -24.37% |
2015 | 5.77M | -71.76% |
2014 | 20.43M | 54.95% |
The current Enterprise Value of Processa Pharmaceuticals, Inc. (PCSA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
24.77M
5-year avg
41.67M
10-year avg
51.48M
Processa Pharmaceuticals, Inc.’s Enterprise Value is less than Alpha Cognition Inc. (57.52M), less than Eupraxia Pharmaceuticals Inc. (115.41M), less than Acurx Pharmaceuticals, Inc. (23.86M), less than Fennec Pharmaceuticals Inc. (105.45M), greater than Comera Life Sciences Holdings, Inc. (-1593200.00), less than SAB Biotherapeutics, Inc. (23.91M), greater than Fresh Tracks Therapeutics, Inc. (-6567217.00), less than Third Harmonic Bio, Inc. (337.19M), less than Eliem Therapeutics, Inc. (119.64M), less than Inhibrx Biosciences, Inc. (4.03M), greater than Merrimack Pharmaceuticals, Inc. (-10189682.00), less than Celcuity Inc. (618.91M), less than Enliven Therapeutics, Inc. (1.21B), less than AN2 Therapeutics, Inc. (5.46M), less than Miromatrix Medical Inc. (90.06M), less than Inhibikase Therapeutics, Inc. (174.48M), less than PMV Pharmaceuticals, Inc. (47.62M), less than Anebulo Pharmaceuticals, Inc. (44.62M), less than Akari Therapeutics, Plc (27.52M), less than Armata Pharmaceuticals, Inc. (205.13M), greater than Scopus BioPharma Inc. (-107741.00),
Company | Enterprise Value | Market cap |
---|---|---|
57.52M | $57.33M | |
115.41M | $108.29M | |
23.86M | $30.22M | |
105.45M | $118.74M | |
-1593200.00 | $3.07K | |
23.91M | $35.81M | |
-6567217.00 | $4.30M | |
337.19M | $588.93M | |
119.64M | $342.68M | |
4.03M | $228.72M | |
-10189682.00 | $223.97M | |
618.91M | $552.86M | |
1.21B | $1.31B | |
5.46M | $32.23M | |
90.06M | $92.95M | |
174.48M | $177.39M | |
47.62M | $83.98M | |
44.62M | $47.72M | |
27.52M | $30.69M | |
205.13M | $85.39M | |
-107741.00 | $16.83K |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Processa Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Processa Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Processa Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Processa Pharmaceuticals, Inc. (PCSA)?
What is the 3-year average Enterprise Value for Processa Pharmaceuticals, Inc. (PCSA)?
What is the 5-year average Enterprise Value for Processa Pharmaceuticals, Inc. (PCSA)?
How does the current Enterprise Value for Processa Pharmaceuticals, Inc. (PCSA) compare to its historical average?